biote Corp. Q4 2025 Earnings Call Summary

Core Insights - The company rebuilt its commercial team, increasing sales personnel from approximately 60 to over 90 to address high clinic attrition, showing results in stabilizing the network by Q4 2025 [1] - The restructuring of the commercial organization focused on servicing existing accounts and driving new clinic starts [1] - Procedure revenue declines were primarily due to higher-than-historical clinic attrition, which accelerated to high single digits in 2024 compared to the typical 5% rate [1] - The strategic focus has shifted towards maximizing value from top-tier clinics by refining contract models and incentive structures for long-term practitioner retention [1] - Operational discipline was enhanced through upgraded data analytics and internal systems, enabling more consistent execution and scalability [1] - Dietary supplement growth of 16% served as a critical hedge, driven by e-commerce expansion and increased patient engagement with healthy aging solutions [1] - Management expressed cautious optimism that foundational work completed in 2025 has positioned the company to reaccelerate procedure revenue growth in the second half of 2026 [1]